Evidence map›Paper›PMID 24692640›Full record

ArticleMolecular & cellular proteomics : MCP2014

SpliceVista, a tool for splice variant identification and visualization in shotgun proteomics data.

Yafeng Zhu, Lina Hultin-Rosenberg, Jenny Forshed, Rui M M Branca, Lukas M Orre, Janne Lehtiö

Abstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Proteoform-Specific Insights into Cellular Proteome Regulation.Molecular & cellular proteomics : MCP · 2016
    Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yafeng ZhuFrom the ‡Cancer Proteomics Mass Spectrometry, Science for Life Laboratory, Karolinska Institutet, 171 65 Stockholm, Sweden.
Lina Hultin-RosenbergFrom the ‡Cancer Proteomics Mass Spectrometry, Science for Life Laboratory, Karolinska Institutet, 171 65 Stockholm, Sweden.
Jenny ForshedFrom the ‡Cancer Proteomics Mass Spectrometry, Science for Life Laboratory, Karolinska Institutet, 171 65 Stockholm, Sweden.
Rui M M BrancaFrom the ‡Cancer Proteomics Mass Spectrometry, Science for Life Laboratory, Karolinska Institutet, 171 65 Stockholm, Sweden.
Lukas M OrreFrom the ‡Cancer Proteomics Mass Spectrometry, Science for Life Laboratory, Karolinska Institutet, 171 65 Stockholm, Sweden.
Janne LehtiöFrom the ‡Cancer Proteomics Mass Spectrometry, Science for Life Laboratory, Karolinska Institutet, 171 65 Stockholm, Sweden janne.lehtio@ki.se.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alternative splicing is a pervasive process in eukaryotic organisms. More than 90% of human genes have alternatively spliced products, and aberrant splicing has been shown to be associated with many diseases. Current methods employed in the detection of splice variants include prediction by clustering of expressed sequence tags, exon microarray, and mRNA sequencing, all methods focusing on RNA-level information. There is a lack of tools for analyzing splice variants at the protein level. Here, we present SpliceVista, a tool for splice variant identification and visualization based on mass spectrometry proteomics data. SpliceVista retrieves gene structure and translated sequences from alternative splicing databases and maps MS-identified peptides to splice variants. The visualization module plots the exon composition of each splice variant and aligns identified peptides with transcript positions. If quantitative mass spectrometry data are used, SpliceVista plots the quantitative patterns for each peptide and provides users with the option to cluster peptides based on their quantitative patterns. SpliceVista can identify splice-variant-specific peptides, providing the possibility for variant-specific analysis. The tool was tested on two experimental datasets (PXD000065 and PXD000134). In A431 cells treated with gefitinib, 2983 splice-variant-specific peptides corresponding to 939 splice variants were identified. Through comparison of splice-variant-centric, protein-centric, and gene-centric quantification, several genes (e.g. EIF4H) were found to have differentially regulated splice variants after gefitinib treatment. The same discrepancy between protein-centric and splice-centric quantification was detected in the other dataset, in which induced pluripotent stem cells were compared with parental fibroblast and human embryotic stem cells. In addition, SpliceVista can be used to visualize novel splice variants inferred from peptide-level evidence. In summary, SpliceVista enables visualization, detection, and differential quantification of protein splice variants that are often missed in current proteomics pipelines.

Indexed as

ProteomicsSoftwareAlternative SplicingDatabases, ProteinExpressed Sequence TagsHumansMass SpectrometryOligonucleotide Array Sequence AnalysisProtein IsoformsProtein Isoforms

Identifiers

PMID24692640
PMCPMC4047474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.